-
Sector Analysis
NewWine Market Opportunities, Trends, Growth Analysis and Forecast to 2028
Wine Market Report Overview The wine market size was valued at $333.7 billion in 2023 and will achieve a CAGR of more than 6% during 2023-2028. The increasing popularity of wine among young consumers will drive market growth during the forecast period. The market growth can also be attributed to the increasing investments by wine companies to improve their technological capabilities to serve consumers better and make wines more disease-resistant. Wine Market Outlook 2023-2028 (USD Billion) Buy the Full Report...
-
Sector Analysis
NewArgentina Cards and Payments – Opportunities and Risks to 2028
Argentina Cards and Payments Market Report Overview The annual value of card transactions in the Argentina cards and payments market was $253.49 billion in 2023 and will grow at a CAGR of more than 68% during 2024-2028. Although cash is the preferred method of payment, there has been a rise in card payments in Argentina. This has been supported by the government’s efforts to boost electronic payments. Argentina Card Transactions Outlook, 2023-2028 ($ Billion) Buy the Full Report for More...
-
Company Insights
NewUnilever – Digital Transformation Strategies
Unilever Digital Transformation Strategies Report Overview Unilever has been focusing on using artificial intelligence, cloud-based mobile applications, big data, and blockchain to digitally transform its operations. The annual ICT spending of Unilever was estimated at $990.3 million for 2023. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. Unilever is a manufacturer and supplier of fast-moving consumer goods. The company's product portfolio comprises food, beauty, personal care, beverages, home care, vitamins, minerals,...
-
Company Insights
NewAvis Budget Group (Avis) – Digital Transformation Strategies
Avis Digital Transformation Strategies Overview Avis Budget Group (Avis) has been focusing on using AI and machine learning, big data, cloud, connected car technology, Internet of Things (IoT), electric vehicles, autonomous vehicles, the future of work, and e-commerce to digitally transform its operations. The annual ICT spending of Avis was estimated at $450.2 million for 2023. A major share of this spending is earmarked for acquiring software, network and communications, and hardware from vendors. Avis offers car sharing as well...
-
Sector Analysis
NewRomania Cards and Payments – Opportunities and Risks to 2028
Romania Cards and Payments Market Report Overview The annual value of card transactions in the Romania cards and payments market was $62.2 billion in 2023 and will grow at a CAGR of more than 12% during 2024-2028. Romania is a cash-dominated market. However, cash usage will continue to decline over the forecast period amid the growing preference for electronic payments and the country’s improving payment infrastructure. Romania Card Transactions Outlook, 2023-2028 ($ Billion) Buy the Full Report for More Information...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MBRC-101 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MBRC-101 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MBRC-101 in Solid Tumor Drug Details: MBRC-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MBRC-101 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MBRC-101 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MBRC-101 in Non-Small Cell Lung Cancer Drug Details: MBRC-101...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MBRC-101 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MBRC-101 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MBRC-101...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MBRC-101 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MBRC-101 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MBRC-101 in Triple-Negative Breast Cancer (TNBC) Drug Details: MBRC-101...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eribulin Mesylate in Metastatic Transitional (Urothelial) Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eribulin Mesylate in Metastatic Transitional (Urothelial) Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eribulin Mesylate in Metastatic Transitional (Urothelial) Tract...